Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 4—April 2021
Research

Emergence of Burkholderia pseudomallei Sequence Type 562, Northern Australia

Ella M. MeumannComments to Author , Mirjam Kaestli, Mark Mayo, Linda Ward, Audrey Rachlin, Jessica R. Webb, Mariana Kleinecke, Erin P. Price, and Bart J. Currie
Author affiliations: Menzies School of Health Research, Darwin, Northern Territory, Australia (E.M. Meumann, M. Kaestli, M. Mayo, L. Ward, A. Rachlin, J.R. Webb, M. Kleinecke, E.P. Price, B.J. Currie); Charles Darwin University, Darwin (E.M. Meumann, M. Kaestli, M. Mayo, L. Ward, A. Rachlin, J.R. Webb, M. Kleinecke, E.P. Price, B.J. Currie); Royal Darwin Hospital, Darwin (E.M. Meumann, B.J. Currie); University of the Sunshine Coast, Sippy Downs, Queensland, Australia (E.P. Price)

Main Article

Table 1

Demographic characteristics and risk factors for melioidosis caused by Burkholderia pseudomallei ST562, Darwin, Australia, October 1, 2004–September 30, 2019*

Characteristic ST, no. (%)†
Bivariate model
Multivariable model
562, n = 53 Other, n = 387 OR (95% CI) p value OR (95% CI) p value
Median age, y (range)
51 (13–85)
53 (1–97)

1.01 (0.99–1.02)
0.49



Sex
F 22 (42) 163 (42) Referent
M
31 (58)
224 (58)

0.98 (0.52–1.81)
>0.99



Ethnicity
Non-Indigenous persons 18 (34) 216 (56) Referent
Aboriginal or Torres Strait Islanders
35 (66)
171 (44)

2.45 (1.30−4.77)
<0.01

1.88 (0.94–3.77)
0.08
Hotspot‡
Creek 17 (33) 40 (11) 3.83 (1.84–7.80) <0.01 4.75 (2.22–10.19) <0.01
Lagoon
11 (21)
18 (5)

5.02 (1.10–12.17)
<0.01

6.10 (2.39–15.54)
<0.01
Underlying condition
Diabetes 28 (53) 177 (46) 1.33 (0.72–2.47) 0.38
Hazardous alcohol consumption 31 (58) 156 (40) 2.08 (1.120–3.93) 0.02 1.72 (0.88–3.36) 0.11
Chronic lung disease 18 (34) 104 (27) 1.40 (0.71–2.67) 0.33
Chronic kidney disease 9 (17) 53 (14) 1.29 (0.52–2.88) 0.53
Congestive cardiac failure or rheumatic heart disease 3 (6) 34 (9) 0.62 (0.12–2.10) 0.60
Malignancy 7 (13) 49 (13) 1.05 (0.39–2.52) 0.83

*OR, odds ratio; ST, sequence type.
†Values are no. (%), except as indicated.
‡Values missing for 1 patient with ST562 and 30 patients with other STs.

Main Article

Page created: February 17, 2021
Page updated: March 18, 2021
Page reviewed: March 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external